Abstract: PO1786
Major Adverse Limb Events and Mortality After Peripheral Artery Revascularization in Hemodialysis Patients
Session Information
- Hypertension and CVD: Clinical, Outcomes, and Trials
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1402 Hypertension and CVD: Clinical, Outcomes, and Trials
Authors
- Lin, Ting-yun, Taipei Tzu Chi Hospital, Taipei, Taiwan
- Hung, Szu-Chun, Taipei Tzu Chi Hospital, Taipei, Taiwan
Background
Revascularization is important for symptom relief and limb salvage in peripheral artery disease, yet limited information exists on the prognosis of hemodialysis patients who receive the procedure. This study sought to determine the incidence and associated factors of major adverse limb events (MALE) after peripheral artery revascularization among hemodialysis patients.
Methods
Hemodialysis patients undergoing peripheral artery revascularization between July 1, 2005, and December 31, 2019, in the Taipei Tzu Chi Hospital were examined for the primary outcome of MALE, defined as severe limb ischemia leading to an intervention or amputation. The secondary outcomes included major adverse cardiovascular events (MACE) and all-cause mortality. Multivariable-adjusted Cox proportional hazards models were used to explore risk factors associated with development of MALE.
Results
A total of 402 hemodialysis patients were included in the final analysis. Overall, the mean age was 68 years, 56.5% (n = 227) were male, 83.3% (n = 335) had diabetes, and 58.0% (n = 233) had coronary artery disease. During a median follow-up of 2.2 years, 54.0% (n = 217) experienced a subsequent MALE, 33.6.0% (n = 136) had a MACE, and 54.5% (n = 219) died. Diabetes, coronary artery disease, current smoking, lower body mass index, and higher platelet count or total cholesterol were significantly associated with increased risk of post-procedure MALE.
Conclusion
A significant proportion of hemodialysis patients undergoing peripheral artery revascularization developed a subsequent MALE and MACE or died. Strategies that address risk factors for MALE should be evaluated to improve the outcomes of revascularized hemodialysis patients.